232 related articles for article (PubMed ID: 18025277)
1. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
[TBL] [Abstract][Full Text] [Related]
3. Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
Janssen S; Jakobsen CM; Rosen DM; Ricklis RM; Reineke U; Christensen SB; Lilja H; Denmeade SR
Mol Cancer Ther; 2004 Nov; 3(11):1439-50. PubMed ID: 15542783
[TBL] [Abstract][Full Text] [Related]
4. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.
Akinboye ES; Rosen MD; Bakare O; Denmeade SR
Bioorg Med Chem; 2017 Dec; 25(24):6707-6717. PubMed ID: 29153549
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
Janssen S; Rosen DM; Ricklis RM; Dionne CA; Lilja H; Christensen SB; Isaacs JT; Denmeade SR
Prostate; 2006 Mar; 66(4):358-68. PubMed ID: 16302271
[TBL] [Abstract][Full Text] [Related]
6. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
7. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.
Denmeade SR; Lou W; Lövgren J; Malm J; Lilja H; Isaacs JT
Cancer Res; 1997 Nov; 57(21):4924-30. PubMed ID: 9354459
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
[TBL] [Abstract][Full Text] [Related]
9. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination.
Satchi-Fainaro R; Hailu H; Davies JW; Summerford C; Duncan R
Bioconjug Chem; 2003; 14(4):797-804. PubMed ID: 12862433
[TBL] [Abstract][Full Text] [Related]
10. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.
Denmeade SR; Nagy A; Gao J; Lilja H; Schally AV; Isaacs JT
Cancer Res; 1998 Jun; 58(12):2537-40. PubMed ID: 9635575
[TBL] [Abstract][Full Text] [Related]
11. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates.
Line BR; Mitra A; Nan A; Ghandehari H
J Nucl Med; 2005 Sep; 46(9):1552-60. PubMed ID: 16157540
[TBL] [Abstract][Full Text] [Related]
12. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts.
Khan SR; Denmeade SR
Prostate; 2000 Sep; 45(1):80-3. PubMed ID: 10960846
[TBL] [Abstract][Full Text] [Related]
13. A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo.
DeFeo-Jones D; Brady SF; Feng DM; Wong BK; Bolyar T; Haskell K; Kiefer DM; Leander K; McAvoy E; Lumma P; Pawluczyk JM; Wai J; Motzel SL; Keenan K; Van Zwieten M; Lin JH; Garsky VM; Freidinger R; Oliff A; Jones RE
Mol Cancer Ther; 2002 May; 1(7):451-9. PubMed ID: 12479263
[TBL] [Abstract][Full Text] [Related]
14. Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles.
Zhou Z; Li L; Yang Y; Xu X; Huang Y
Biomaterials; 2014 Aug; 35(24):6622-35. PubMed ID: 24814427
[TBL] [Abstract][Full Text] [Related]
15. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
[TBL] [Abstract][Full Text] [Related]
16. Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates.
Yang Y; Zhou Z; He S; Fan T; Jin Y; Zhu X; Chen C; Zhang ZR; Huang Y
Biomaterials; 2012 Mar; 33(7):2260-71. PubMed ID: 22189143
[TBL] [Abstract][Full Text] [Related]
17. PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination.
Satchi R; Connors TA; Duncan R
Br J Cancer; 2001 Sep; 85(7):1070-6. PubMed ID: 11592781
[TBL] [Abstract][Full Text] [Related]
18. Targeted prodrug approaches for hormone refractory prostate cancer.
Aloysius H; Hu L
Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
[TBL] [Abstract][Full Text] [Related]
19. Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.
Borgman MP; Ray A; Kolhatkar RB; Sausville EA; Burger AM; Ghandehari H
Pharm Res; 2009 Jun; 26(6):1407-18. PubMed ID: 19225872
[TBL] [Abstract][Full Text] [Related]
20. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
Wong BK; DeFeo-Jones D; Jones RE; Garsky VM; Feng DM; Oliff A; Chiba M; Ellis JD; Lin JH
Drug Metab Dispos; 2001 Mar; 29(3):313-8. PubMed ID: 11181501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]